Flag of the European Union EU Clinical Trials Register Help

Clinical trials for In situ hybridization

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    294 result(s) found for: In situ hybridization. Displaying page 15 of 15.
    «« First « Previous 7  8  9  10  11  12  13  14  15 
    EudraCT Number: 2017-002781-48 Sponsor Protocol Number: MedOPP068 Start Date*: 2019-02-08
    Sponsor Name:Medica Scientia Innovation Research (MedSIR)
    Full Title: INTERNATIONAL, MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CONTINUATION OF PALBOCICLIB IN COMBINATION WITH SECOND-LINE ENDOCRINE THERAPY IN H...
    Medical condition: Hormone receptor-positive/HER2-negative Advanced Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) DE (Completed) SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013838-25 Sponsor Protocol Number: IMCLCP11-0806 Start Date*: 2009-10-21
    Sponsor Name:ImClone LLC
    Full Title: A Randomized, Multicenter, Open-Label, Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of...
    Medical condition: Advanced squamous non small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) DE (Completed) HU (Completed) PT (Completed) ES (Ongoing) GR (Ongoing) SK (Completed) IT (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2015-000617-43 Sponsor Protocol Number: CLEE011F2301 Start Date*: 2015-05-27
    Sponsor Name:Novartis Pharma Services AG
    Full Title: MONALEESA-3: A randomized double-blind, placebo-controlled study of ribociclib in combination with fulvestrant for the treatment of men and postmenopausal women with hormone receptor positive, HER2...
    Medical condition: men and postmenopausal women with HR+, HER2-negative advanced (loco regionally recurrent not amenable to curative therapy or metastatic) breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) AT (Completed) ES (Completed) CZ (Completed) DK (Completed) NL (Completed) HU (Completed) BE (Completed) BG (Completed) FR (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003302-40 Sponsor Protocol Number: WO40242 Start Date*: 2018-04-10
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY AFTER DEFINITIVE LOCAL THERAPY IN PATIENTS WITH HIGH-RISK LOCA...
    Medical condition: Locally advanced squamous cell carcinoma of the head and neck (SCCHN)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041823 Squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) PL (Completed) FR (Completed) BE (Completed) PT (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000789-13 Sponsor Protocol Number: ISA101b-HN-01-17 Start Date*: 2019-02-05
    Sponsor Name:ISA Therapeutics B.V.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Oropharyngeal Cancer (...
    Medical condition: HPV16-Positive Oropharyngeal Cancer (OPC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031098 Oropharyngeal cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Completed) CZ (Completed) ES (Ongoing) BE (Completed) HU (Completed) NL (Ongoing) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001862-41 Sponsor Protocol Number: CBYL719A2201 Start Date*: 2013-11-26
    Sponsor Name:Novartis Farmacéutica , S.A.
    Full Title: A phase II randomized, double-blind placebo controlled, study of letrozole with or without BYL719 or buparlisib, for the neoadjuvant treatment of postmenopausal women with hormone receptor-positive...
    Medical condition: neoadjuvant hormone-receptor positive HER2-negative breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) IT (Completed) AT (Completed) BE (Completed) DE (Completed) NL (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-000650-11 Sponsor Protocol Number: HEP002 Start Date*: 2014-09-15
    Sponsor Name:Promethera Biosciences
    Full Title: A prospective, open label, multicountry, efficacy and safety study of several infusions of HepaStem in Urea Cycle Disorders pediatric patients.
    Medical condition: The urea cycle disorders are inborn errors of metabolism that affect the transfer of nitrogen into urea. There are seven disorders to be investigated: carbamoylphosphate synthetase I deficiency [CP...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10013373 Disorders of urea cycle metabolism LLT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-000079-35 Sponsor Protocol Number: J2J-OX-JZLC Start Date*: 2021-11-02
    Sponsor Name:Eli Lilly and Company
    Full Title: EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive, HER2 Neg...
    Medical condition: Breast Neoplasms, Neoplasm Metastasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) DE (Ongoing) CZ (Completed) FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001151-68 Sponsor Protocol Number: TUD-APOLLO-064 Start Date*: 2016-05-19
    Sponsor Name:Technische Universität Dresden
    Full Title: A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracyclines-based chemotherapy (AIDA regimen) for patients with newly diag...
    Medical condition: newly diagnosed high-risk acute promyelocytic leukemia (APL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001019 Acute promyelocytic leukaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Ongoing) NL (Prematurely Ended) BE (Completed) ES (Ongoing) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-005932-24 Sponsor Protocol Number: CBKM120F2202 Start Date*: 2012-07-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo controlled, phase II/III study of BKM120 plus paclitaxel in patients with HER2 negative inoperable locally advanced or metastatic breast cancer, with or without ...
    Medical condition: This study will evaluate whether the addition of daily BKM120 to weekly paclitaxel is effective and safe in treating patients with HER2- locally advanced or metastatic breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) CZ (Completed) ES (Temporarily Halted) NL (Completed) GB (Completed) BE (Completed) HU (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005843-40 Sponsor Protocol Number: PXD101-CLN-19 Start Date*: 2008-11-11
    Sponsor Name:Spectrum Pharmaceuticals Inc.
    Full Title: A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
    Medical condition: Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004851 10034622 Peripheral T-cell lymphomas NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) FR (Completed) IT (Completed) NL (Completed) BE (Completed) DE (Completed) ES (Completed) HU (Completed) SK (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-000601-74 Sponsor Protocol Number: PCI-32765MCL3001 Start Date*: 2014-01-24
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects with Relapsed or Refractory Mantle Cell L...
    Medical condition: Relapsed or refractory Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026801 Mantle cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) DE (Completed) GB (Completed) IE (Completed) HU (Completed) PT (Completed) CZ (Completed) NL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002455-42 Sponsor Protocol Number: WO41554 Start Date*: 2020-08-21
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN ...
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Completed) HU (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005269-15 Sponsor Protocol Number: CO42865 Start Date*: 2022-05-18
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL STUDY OF PRALSETINIB VERSUS STANDARD OF CARE FOR TREATMENT OF RET-MUTATED MEDULLARY THYROID CANCER
    Medical condition: RET-mutated Medullary Thyroid Cancer (MTC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027105 Medullary thyroid cancer PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended) DK (Prematurely Ended) BE (Prematurely Ended) BG (Completed) PL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 7  8  9  10  11  12  13  14  15 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 00:17:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA